Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 270 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatic Failure Clear all

Conditions: Severe Hepatic Veno-Occlusive Disease
Interventions: Defibrotide; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 22
States / cities: Duarte, California • Palo Alto, California • Denver, Colorado + 19 more

Conditions: Hepatic Insufficiency
Interventions: Ipatasertib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Miami, Florida • Knoxville, Tennessee • San Antonio, Texas

Conditions: Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
Interventions: NBI-98854 50 mg capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota

Conditions: Cancer, Chronic Obstructive Pulmonary Disease, Heart Failure, Dementia, End Stage Liver Disease, End Stage Renal Disease, Neuromuscular Diseases
Interventions: Tech-supported HBPC, Standard HBPC; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 3,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Pasadena, California • Portland, Oregon

Conditions: Liver Transplant; Complications
Interventions: Prehabilitation intervention, Caregiver intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 74 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Acute Liver Injury
Interventions: Not listed
Lead sponsor: William Lee; Other
Eligibility: 18 Years and older
Enrollment: 3,488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Ventilation, ARDS, Respiratory Failure, Mechanical Ventilation, Ventilator-induced Lung Injury (VILI), Quality Improvement, Ventilator Associated Events
Interventions: RKP Monitoring Software; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: Up to 100 Years
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Acute and Chronic Hepatic Failure With Developing Coma
Interventions: Not listed
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Hepatic Encephalopathy
Interventions: sodium phenylacetate and sodium benzoate injection 10% / 10%, placebo solution (10% dextrose); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Fresno, California • Loma Linda, California • Odessa, Texas

Conditions: Telomere Disease
Interventions: Danazol; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 3 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congestive Heart Failure
Interventions: Heart Self Care Tracker, Heart Care Self Tracker; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: End Stage Liver Disease, Decompensated Cirrhosis of Liver
Interventions: Palliative Care; Other
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1,494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 15 more

Conditions: Liver Failure Acute
Interventions: human hepatocytes; Drug
Lead sponsor: Ira Fox; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: End Stage Liver Disease, Hepatitis C
Interventions: Daclizumub, Tacrolimus, Cyclosporine, MMF; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cirrhosis, End Stage Liver Disease, Hepatitis C
Interventions: Screening; Procedure
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver, Advanced Cirrhosis
Interventions: LiverPAL; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure, Liver Failures, Chronic, Renal Insufficiency, Chronic, Dementia, Diabetes Complications, Peripheral Vascular Disease, Frail Elderly
Interventions: Jumpstart Intervention; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Hepatic Encephalopathy
Interventions: Home Recordings, In-patient Recordings, Same-Day Study Visit - Regular Appointment, Same-Day Study Visit - Procedure, Phone Call Follow-up Visits; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatic Encephalopathy
Interventions: Placebo, Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more

Conditions: Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Interventions: Siplizumab; Drug
Lead sponsor: Elizabeth C. Verna; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: End Stage Liver Disease
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 74 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Failure
Interventions: Liver Transplant; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: End Stage Liver Disease
Interventions: LYG-LIV0001; Biological
Lead sponsor: LyGenesis, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

Comparative Trial of Home-Based Palliative Care

Identifying Perceived Barriers and Facilitators Toward a Liver Transplantation Prehabilitation

A Multi-Center Trial to Study Acute Liver Failure in Adults

Respiratory Knowledge Portal Computer and Phone Application to Improve Quality of Mechanical Ventilation by Reducing the Number of Ventilator Associated Events, Injury Created by the Ventilator and Unsafe Setting of Alarms.

Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

Low-Dose Danazol for the Treatment of Telomere Related Diseases

Heart Failure Patient Self-Management Web Portal Pilot Study

Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)

Hepatocyte Transplantation for Acute Decompensated Liver Failure

Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease

LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease

Project to Improve Communication About Serious Illness - Pilot Study

Speech in Hepatic Encephalopathy (HE)

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

A Study of SIPLIZUMAB in AILD and LT Patients

Psychosocial Risks in Liver Transplant Recipients

Superior Vena Cava and Its Relationship to Central Venous Pressure Measurements in Liver Transplantation

Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes

Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy